Higher-Dose Semaglutide (7.2 mg) Yields Drives Greater Weight and Glycemic Benefits in T2D Read more about Higher-Dose Semaglutide (7.2 mg) Yields Drives Greater Weight and Glycemic Benefits in T2D
Transforming Cardio Metabolic Outcomes with GLP-1 Medicines Tags GLP-1 agonists Read more about Transforming Cardio Metabolic Outcomes with GLP-1 Medicines
Modernising Diabetes Care Tags Continuous glucose monitoring (CGM) Read more about Modernising Diabetes Care
Updates on Diabetic Kidney Disease Tags Diabetic Nephropathy Read more about Updates on Diabetic Kidney Disease
MR Imaging Reveals Distinct Liver Fat Profiles Across Diabetes Subtypes Read more about MR Imaging Reveals Distinct Liver Fat Profiles Across Diabetes Subtypes
Fewer Dementia Cases With SGLT2 Inhibitors vs DPP-4 Inhibitors in Older Adults With T2D Read more about Fewer Dementia Cases With SGLT2 Inhibitors vs DPP-4 Inhibitors in Older Adults With T2D
Once-Weekly GLP-1 RAs Reduce Cardiovascular Events and Costs in T2D with ASCVD Tags Cardiomyopathy Read more about Once-Weekly GLP-1 RAs Reduce Cardiovascular Events and Costs in T2D with ASCVD
CCTA Rules Out Risk in R-AAOCA, Nuclear Imaging Confirms High-Risk Cases Read more about CCTA Rules Out Risk in R-AAOCA, Nuclear Imaging Confirms High-Risk Cases
Glucose Control Above 50% Time in Range Lowers Perinatal Risks in Type 1 Diabetes Read more about Glucose Control Above 50% Time in Range Lowers Perinatal Risks in Type 1 Diabetes
